

Ellage[®] Anhydrous Vaginal

An Anhydrous Base for Compounded Vaginal Medications With Prolonged Beyond-Use Dates



PCCA # 30-5110

Ellage Anhydrous Vaginal is the first anhydrous base in pharmacy compounding developed specifically for vaginal applications. It is designed to be gentle on vaginal tissue, release drugs and maintain contact with the mucosa, all while providing a uniquely pleasant experience for patients with various health challenges who need compounded vaginal medication.

With water activity less than 0.6 ($A_w < 0.6$), Ellage is classified as an anhydrous vehicle, which allows pharmacy compounders to assign longer default beyond-use dates (BUDs) — without sacrificing performance or elegance.

Ellage Anhydrous Vaginal is made of pharmaceutical-grade ingredients and can accommodate a variety of drugs, including:

- Hormones
- Antimicrobials
- Antifungals
- Anti-inflammatories
- Anesthetics
- Vasodilators

This broad compatibility, combined with its gentle and nonirritating composition, means that Ellage is ideal in formulations for patients with a wide variety of vaginal conditions.

BENEFITS FOR COMPOUNDERS

- **Prolonged default BUDs:** Ellage is anhydrous, allowing preparations to have longer BUDs by default, which increases operational efficiency and saves compounders thousands of dollars in stability testing
- **Broad API compatibility:** Ellage is a stable, anhydrous vehicle appropriate for a variety of active pharmaceutical ingredients (APIs), including hormones, antimicrobials, antifungals, anti-inflammatories, anesthetics and vasodilators
- **Better patient compliance:** Ellage is nonirritating and has significant potential to minimize leakage, which may increase patient compliance



BENEFITS FOR PATIENTS

- **Potentially reduced leakage:** *In vitro* testing shows that Ellage has significant potential to minimize leakage of medication, offering a superior patient experience
- **No irritation:** Ellage is nonirritating and incredibly gentle on mucosal tissue, providing a pleasant base for customized vaginal medications

RELATED SPECIALTIES

- Gynecology
- Urology
- Family practice
- Internal medicine
- Functional medicine



Continued on the next page

Ellage[®] Anhydrous Vaginal

FORMULATED WITHOUT

- Wheat
- Milk
- Egg
- Soy
- Fish (including crustacean)
- Peanut
- Almond
- Pecan
- Macadamia
- Walnut
- Hazelnut
- Gluten

HOW DOES ELLAGE WORK?

Ellage Anhydrous Vaginal contains a self-emulsifying drug delivery system that creates a micro-emulsion when it comes in contact with water in vaginal fluid. This emulsion releases the active ingredients from the base to the mucosa. Once the active ingredients are released, the emulsifier system in the base also holds the drugs to the surface and increases the contact time. This combination of excellent drug release and adherence to mucosal tissue makes Ellage an ideal base for vaginal applications.



THE PROOF

The results of *in vitro* testing show that Ellage Anhydrous Vaginal releases drugs comparably to VersaBase[®] Cream, the industry standard for compounded vaginal medicine. The PCCA Science team has published studies showing how well it releases estriol and testosterone as well as amitriptyline and baclofen.^{1,2}

Additional testing has shown that Ellage's self-emulsifying and mucoadhesive properties give it the potential to maximize drug solubility and bioavailability while increasing the contact time between APIs and vaginal tissue. Importantly, the base exhibited the ability to self-emulsify even in the presence of small amounts of simulated vaginal fluid, as might be expected with cases of vaginal dryness. PCCA Science has published two studies evaluating the base's self-emulsifying drug delivery system, one using a texture analyzer and one using a fluorescent dye.^{3,4} They have published two studies testing its mucoadhesion as well, one employing traditional microscopic evaluation and one employing fluorescence microscopy.^{5,6}

PCCA Science has also published *in vitro* studies showing that Ellage is nonirritating for vaginal tissue,^{7,8} it does not affect vaginal pH,^{9*} and it is likely to adhere to vaginal tissue for a long period of time without leakage or messiness despite regular vaginal secretions.¹⁰

FORMULATION EXAMPLES

- **PCCA Formula #13845**
Estriol 0.1%/Testosterone 0.1% Vaginal (Ellage Anhydrous)
- **PCCA Formula #13944**
Estriol/Estradiol [50%/50%] 0.5 mg/Gm Vaginal (Ellage Anhydrous)
- **PCCA Formula #13834**
Amitriptyline HCl 2%/Baclofen 2% Vaginal (Ellage Anhydrous)
- **PCCA Formula #13849**
Gabapentin 6% Vaginal (Ellage Anhydrous)
- **PCCA Formula #13860**
Naltrexone HCl 0.5% Topical/Vaginal (Ellage Anhydrous)

For more example formulas, PCCA members can visit bit.ly/ellage-formulas.

Continued on the next page

Ellage[®] Anhydrous Vaginal

FREQUENTLY ASKED QUESTIONS

Does Ellage replace VersaBase Cream or MucoLox[™]/VersaBase Gel for vaginal compounds?

While VersaBase Cream and the combination of MucoLox and VersaBase Gel are well established as options for vaginal compounds, Ellage Anhydrous Vaginal is an anhydrous option to consider when starting a patient on a vaginal preparation. If a patient and her prescriber are pleased with her current compounded medication, however, we recommend not changing that compound.

Can Ellage be used for other applications than vaginal?

Yes, Ellage can also be used for topical rectal applications commonly requested for patients with anal fissures and external hemorrhoids. It could also be a good option for formulas commonly requested for patients with diaper rash.

Should pharmacy compounders transition patients who are using other bases to Ellage?

It depends on the situation. Ellage Anhydrous Vaginal is a great option when starting a new patient on a vaginal formulation. Also, if a patient is experiencing symptoms with her current medication, changing the base instead of the dose may be a good option, in which case this base is a consideration. However, if a patient and her prescriber are pleased with her current compounded medication, we recommend not changing that compound.

Which dispensing devices should pharmacy compounders use with Ellage?

The Topi-Click[®] Perl[™] 35 mL Vaginal Dosing Kit (PCCA #35-5480) is our recommendation for dispensing preparations made with Ellage Anhydrous Vaginal. Our Exacta-Med oral/topical syringes (0.5 mL to 10 mL) are options as dispensing devices too.

** Ingredients that are incorporated into the base could potentially affect the vaginal pH.*

PLEASE NOTE

Always make sure you have checked the PCCA formula database and are following the most up-to-date version of a formula, as changes are continually made to existing formulations to provide the highest quality. The formulas and/or statements listed are provided for educational purposes only. They are compounding ideas that have commonly been requested by physicians and have not been evaluated by the Food and Drug Administration. Formulas and/or material listed are not to be interpreted as a promise, guarantee, or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

REFERENCES

1. PCCA Science. (2020). In vitro drug release of estriol 0.1% and testosterone 0.1% from VersaBase Cream and PCCA Ellage Anhydrous Vaginal [PCCA Document #99823]. https://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99823_TR_Ellage-DrugRelease-E3-Test.pdf
2. PCCA Science. (2020). In vitro drug release of amitriptyline 2% and baclofen 2% from VersaBase Cream and PCCA Ellage Anhydrous Vaginal [PCCA Document #99824]. https://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99824_TR_Ellage-DrugRelease-AmitrBaclof.pdf
3. PCCA Science. (2020). Evaluation of the mucoadhesive properties of PCCA Ellage part 1: Ex vivo bioadhesion testing using a texture analyzer [PCCA Document #99836]. http://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99836_TR_Ellage-MucoadhTexture-Part-1.pdf
4. PCCA Science. (2020). Evaluation of the mucoadhesive properties of PCCA Ellage part 2: Ex vivo testing on animal vaginal tissues [PCCA Document #99837]. http://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99837_TR_Ellage-MucoadhAnimalTissue-Part-2.pdf
5. PCCA Science. (2020). Evaluation of the self-emulsifying properties of PCCA Ellage part 1: Microscopic evaluation [PCCA Document #99838]. http://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99838_TR_Ellage-Self-EmulsProp-Part1.pdf
6. PCCA Science. (2020). Evaluation of the self-emulsifying properties of PCCA Ellage part 2: Fluorescence microscopy [PCCA Document #99839]. http://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99839_TR_Ellage-Self-EmulsProp-Part2.pdf
7. PCCA Science. (2020). Evaluation of the irritation potential of PCCA Ellage Anhydrous Vaginal part 1: Hen's egg test-chorioallantoic membrane assay [PCCA Document #99817]. [https://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99817_Ellage-TR%20Irritation%20\(Part%201\).pdf](https://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99817_Ellage-TR%20Irritation%20(Part%201).pdf)
8. PCCA Science. (2020). Evaluation of the irritation potential of PCCA Ellage Anhydrous Vaginal part 2: Safety and toxicological profile by the MTT assay [PCCA Document #99818]. https://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99818_TR_Ellage-MucosalToxic-Part-2.pdf
9. PCCA Science. (2020). Effect of Ellage and other PCCA proprietary bases on the pH of vaginal fluid [PCCA Document #99815]. https://beta.pccarx.com/pdf_files/PCCA%20Science/Technical%20Reports/99815_TR_Ellage-VaginalpH.pdf

USA: 800.331.2498 pccarx.com | Canada: 800.668.9453 pccarx.ca | Australia: 02.9316.1500 pccarx.com.au | UK: 0800.038.5095 pccarx.co.uk

